Treatment of Pituitary Adenomas
نویسندگان
چکیده
منابع مشابه
[Treatment of pituitary adenomas].
There has been a dramatic development in the treatment of pituitary adenomas during the last two decades. The main factors which led to this development were the introduction of transsphenoidal surgery, the development of new imaging modalities such as computed tomography (CT) and magnetic resonance imaging (MRI) and the introduction of newer dopaminergic agents. Present status of the treatment...
متن کاملMultimodality treatment of pituitary adenomas.
Acromegaly is caused by excessive secretion of growth hormone (GH). The average annual incidence of acromegaly is approximately 3.3 per million, and the prevalence is approximately 60 per million (50). GH-secreting adenomas account for 20% of functional adenomas, and 75% of GH adenomas are macroadenomas (50). The mortality in untreated acromegaly is two to three times higher than that of the ge...
متن کاملChapter 16. Surgical Treatment of Pituitary Adenomas
Pituitary adenomas may be classified either according to their size or their functional status (Table 1). Those tumors that measure 10 mm or less in diameter are considered microadenomas; macroadenomas are those larger than 10 mm. Macroadenomas may also be sub-categorized as "giant" if their extent reaches far beyond the normal confines of the pituitary region or their greatest diameter exceeds...
متن کاملSurgical treatment of giant pituitary adenomas.
Multidirectional extension and invasive spread are important features of giant pituitary adenomas. Operability cannot be established merely by determining the size of the most prominent part of the tumour. Detailed radiological evaluation with plain films, computed tomography, angiography, and air studies all contribute to evaluation of the precise anatomy before surgery. In the final decision ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Folia Endocrinologica Japonica
سال: 1992
ISSN: 0029-0661
DOI: 10.1507/endocrine1927.68.8_711